OBJECTIVE: Lung adenocarcinomas 2 cm or less in diameter were studied to develop histologic criteria predicting the outcome. MATERIALS AND METHODS: We reviewed 510 consecutive lung adenocarcinomas 2 cm or less in diameter and assessed three histologic parameters to implement a histologic scoring system: lymphovascular invasion, maximum diameter of the nonbronchioloalveolar carcinoma (BAC) component, and percentage of the solid, cribriform, and/or papillary component in the entire tumor volume (%solid/cribriform/papillary). One point was given to each of lymphovascular invasion-positive, non-BAC >10 mm and %solid/cribriform/papillary > or =30%, and by the sum of these points, a score of 0 to 3 was assigned for each tumor. We also evaluated minimally invasive adenocarcinomas comprising non-BAC < or =5 mm, Sakurai grades 1 and 2. RESULTS: Five-year disease-free survival rates of 287 patients with a histologic score of 0, 69 with a score of 1, 64 with a score of 2, and 90 with a score of 3 were 98.9%, 92.4%, 78.4%, and 54.0%, respectively. The 510 tumors included 129 noninvasive and 127 minimally invasive adenocarcinomas. None of these tumors recurred. In remaining 254 patients with overtly invasive adenocarcinomas, 5-year disease-free survival rates in 51 with a histologic score of 0, 49 with a score of 1, 64 with a score of 2, and 90 with a score of 3 were 95.9%, 89.2%, 79.4%, and 54.2%, respectively. CONCLUSION: The histologic scoring system comprising lymphovascular invasion-positive, non-BAC >10 mm and %solid/cribriform/papillary > or =30% is able to predict the outcome of lung adenocarcinomas 2 cm or less in diameter not only in all cases but also in overtly invasive adenocarcinomas. Minimally invasive adenocarcinomas did not recur in this large series.
OBJECTIVE:Lung adenocarcinomas 2 cm or less in diameter were studied to develop histologic criteria predicting the outcome. MATERIALS AND METHODS: We reviewed 510 consecutive lung adenocarcinomas 2 cm or less in diameter and assessed three histologic parameters to implement a histologic scoring system: lymphovascular invasion, maximum diameter of the nonbronchioloalveolar carcinoma (BAC) component, and percentage of the solid, cribriform, and/or papillary component in the entire tumor volume (%solid/cribriform/papillary). One point was given to each of lymphovascular invasion-positive, non-BAC >10 mm and %solid/cribriform/papillary > or =30%, and by the sum of these points, a score of 0 to 3 was assigned for each tumor. We also evaluated minimally invasive adenocarcinomas comprising non-BAC < or =5 mm, Sakurai grades 1 and 2. RESULTS: Five-year disease-free survival rates of 287 patients with a histologic score of 0, 69 with a score of 1, 64 with a score of 2, and 90 with a score of 3 were 98.9%, 92.4%, 78.4%, and 54.0%, respectively. The 510 tumors included 129 noninvasive and 127 minimally invasive adenocarcinomas. None of these tumors recurred. In remaining 254 patients with overtly invasive adenocarcinomas, 5-year disease-free survival rates in 51 with a histologic score of 0, 49 with a score of 1, 64 with a score of 2, and 90 with a score of 3 were 95.9%, 89.2%, 79.4%, and 54.2%, respectively. CONCLUSION: The histologic scoring system comprising lymphovascular invasion-positive, non-BAC >10 mm and %solid/cribriform/papillary > or =30% is able to predict the outcome of lung adenocarcinomas 2 cm or less in diameter not only in all cases but also in overtly invasive adenocarcinomas. Minimally invasive adenocarcinomas did not recur in this large series.
Authors: Fabien Maldonado; Jennifer M Boland; Sushravya Raghunath; Marie Christine Aubry; Brian J Bartholmai; Mariza Deandrade; Thomas E Hartman; Ronald A Karwoski; Srinivasan Rajagopalan; Anne-Marie Sykes; Ping Yang; Eunhee S Yi; Richard A Robb; Tobias Peikert Journal: J Thorac Oncol Date: 2013-04 Impact factor: 15.609
Authors: William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz Journal: J Thorac Oncol Date: 2011-02 Impact factor: 15.609
Authors: Luisa M Solis; Carmen Behrens; M Gabriela Raso; Heather Y Lin; Humam Kadara; Ping Yuan; Hector Galindo; Ximing Tang; J Jack Lee; Neda Kalhor; Ignacio I Wistuba; Cesar A Moran Journal: Cancer Date: 2011-10-21 Impact factor: 6.860
Authors: Kyuichi Kadota; Jonathan Villena-Vargas; Akihiko Yoshizawa; Noriko Motoi; Camelia S Sima; Gregory J Riely; Valerie W Rusch; Prasad S Adusumilli; William D Travis Journal: Am J Surg Pathol Date: 2014-04 Impact factor: 6.394
Authors: Kyuichi Kadota; Yi-Chen Yeh; Camelia S Sima; Valerie W Rusch; Andre L Moreira; Prasad S Adusumilli; William D Travis Journal: Mod Pathol Date: 2013-11-01 Impact factor: 7.842